Navigation Links
Change in PSA level does not predict prostate cancer
Date:2/24/2011

NEW YORK, February 24, 2011 Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time known as PSA velocity is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The new study of more than 5,000 men was published online February 24 in the Journal of the National Cancer Institute. Andrew Vickers, PhD, Associate Attending Research Methodologist in the Department of Epidemiology and Biostatistics and lead author said, "We have found no evidence to support the recommendation that men with a high PSA velocity should be biopsied in the absence of other indications. In other words, if a man's PSA has risen rapidly in recent years, there is no cause for concern if his total PSA level is still low and his clinical exam is normal."

Prostate cancer is the most common cancer among American men and the second leading cause of cancer deaths in men, according to the American Cancer Society. While PSA screening is widely used for the early detection of prostate cancer, it is also associated with a high rate of overdiagnosis, which can lead to unnecessary treatment and anxiety. Currently, early detection guidelines of several organizations (the National Cancer Center Network and the American Urological Association) recommend that men with a rapid rise in PSA or a high PSA velocity have a surgical biopsy for prostate cancer, even if there are no other indicators that cancer may exist. Those indicators could be an elevated baseline PSA or a positive digital rectal exam (DRE).

This study's population came from the Prostate Cancer Prevention Trial. Five thousand five hundred and nineteen men aged 55 years and older with no previous prostate cancer diagnosis, normal DRE, and a baseline PSA of 3.0 ng/mL or less were randomly assigned to finasteride a drug commonly used to treat enlargement of the prostate gland, more commonly referred to as BPH, or benign prostatic hypertrophy or placebo for seven years. This particular study focused on the men in the placebo group. The men were followed with yearly PSA tests, with biopsy recommended for men with a PSA higher than 4.0 ng/mL. After seven years, all men who were not diagnosed with prostate cancer were asked to consent to an end-of-study biopsy.

Dr. Vickers and colleagues found no important association between PSA velocity and biopsy outcome after adjusting for risk factors such as age, race, and PSA levels. PSA alone was a much better predictor of biopsy outcome than PSA velocity.

According to Peter T. Scardino, MD, Chair of the Department of Surgery, "This study should change practice. We have previously published papers determining that PSA naturally varies from month to month and have urged men whose PSA suddenly rises to wait six weeks and repeat the test before agreeing to a needle biopsy. This new study in a large population of men provides even stronger evidence that using changes in PSA as a basis for recommendation for biopsy leads to many more unnecessary biopsies and does not help to find the more aggressive cancers that we want to find and treat." Dr. Scardino added that "men should be cautious before rushing into a biopsy for minor variations in their PSA level."


'/>"/>

Contact: Courtney DeNicola Nowak
denicolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Physical Changes in Brain Linked to Altered Spirituality
2. Whitemark Homes Inc. Announces Change of Auditors and Additional Corporate Information
3. Apptix Signs 100,000 Seat Hosted Exchange Email Contract
4. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
5. Tyco International Announces Exchange Rate for Quarterly Dividend
6. MARC Coalition Applauds Agencys Alert Regarding Delay in Data Exchange Deadline
7. Medicare Advantage Members May Make Changes During Open Enrollment
8. Clearwave Corporation Creates Healthcare's First Patient-Facing Network Exchange
9. CMS Watch Changes Name to The Real Story Group
10. Changes during menopause increases risk of heart disease and stroke
11. Access to Mammograms Drops After Guidelines Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the ... located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the ... living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... 2017 , ... The IoT (Internet of Things) is revolutionizing the way the ... on businesses and individual consumers alike. Laboratories can maximize their profit margin by ... from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the ...
(Date:3/23/2017)... NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware of ... kids do not brush their teeth the minimum two times a day that dentists recommend. ... students missing 51 million hours of school and adults missing 164 million hours of work ...
(Date:3/23/2017)... ... March 23, 2017 , ... March is National Kidney Month ... punch when it comes to maintaining good health. Every day, two kidneys filter about ... filter every drop of your blood, eliminating waste, regulating fluid levels and blood pressure, ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... VANCOUVER , March 23, 2017 /PRNewswire/ - INVICTUS ... OTC: IVITF; FRA: 8IS) Invictus MD announces that AB ... crops in its licensed production facility under the Access ... Hamilton, Ontario . ... ACMPR in October 2016, is currently operating at half ...
(Date:3/23/2017)... New York , March 23, 2017 /PRNewswire/ ... market exhibits a consolidated vendor landscape with the top ... overall market in 2015. These companies are Stryker ... Inc., Hygia Health Services, Inc., and VANGUARD AG. ... reprocessed medical devices market is witnessing the prevalence ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
Breaking Medicine Technology: